{"product_id":"abcam-ab140613","title":"Abcam, ab140613, Anti-alpha 1,2 Mannosidase IA\/MAN1A1 antibody [EPR9957(B)]","description":"\u003cp\u003eSize: 100µL \/ 1mL\u003cbr\u003e\nRabbit Recombinant Monoclonal alpha 1,2 Mannosidase IA\/MAN1A1 antibody. Suitable for WB and reacts with Human samples. Cited in 7 publications.\u003cbr\u003e\nKey facts\u003cbr\u003e\nHost species:Rabbit,\u003cbr\u003e\nClonality:Monoclonal,\u003cbr\u003e\nClone number:EPR9957(B),\u003cbr\u003e\nIsotype:IgG,\u003cbr\u003e\nCarrier free:No,\u003cbr\u003e\nReacts with:Human,\u003cbr\u003e\nApplications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,\u003cbr\u003e\nImmunogen:The exact immunogen used to generate this antibody is proprietary information.\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nSpecies reactivity\u003cbr\u003e\nMouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.\u003cbr\u003e\nPlease\u003cbr\u003e\ncontact us\u003cbr\u003e\nfor more information.\u003cbr\u003e\nPatented technology\u003cbr\u003e\nOur RabMAb\u003cbr\u003e\ntechnology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to\u003cbr\u003e\nRabMAb® patents\u003cbr\u003e\nWhat are the advantages of a recombinant monoclonal antibody?\u003cbr\u003e\nThis product is a recombinant monoclonal antibody, which offers several advantages including:\u003cbr\u003e\n- High batch-to-batch consistency and reproducibility\u003cbr\u003e\n- Improved sensitivity and specificity\u003cbr\u003e\n- Long-term security of supply\u003cbr\u003e\n- Animal-free batch production\u003cbr\u003e\nFor more information, read more on\u003cbr\u003e\nrecombinant antibodies\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nForm-Liquid, Purity-Tissue culture supernatant, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nAlpha 12 Mannosidase IA also known as MAN1A1 is an enzyme that catalyzes the hydrolysis of terminal α-D-mannose residues in the N-glycan processing pathway. This enzyme functions as a mannosyl-oligosaccharide 12-alpha-mannosidase and its molecular mass is approximately 73 kDa. MAN1A1 is expressed in various tissues including high expression levels in the liver and kidney. The enzyme has a significant role in the Golgi apparatus of cells where it contributes to glycoprotein maturation by trimming mannose residues.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nAlpha 12 Mannosidase IA influences glycoprotein quality control by processing N-linked glycans. As part of the glycosylation machinery this enzyme ensures proper protein folding and stability. MAN1A1 does not directly form part of a multiprotein complex but interacts with various substrates during the glycan trimming process. This interaction helps in determining the fate of glycoproteins and their proper cellular localization.\u003cbr\u003e\nPathways\u003cbr\u003e\nAlpha 12 Mannosidase IA plays an important role in the N-glycan biosynthesis and processing pathway where it alters the structure of N-glycans by removing mannose residues. This enzyme is connected to the calnexin\/calreticulin cycle an important element of glycoprotein maturation. Related proteins such as glucosidase II further process the glycoproteins as they mature in the Golgi apparatus. This sequential processing is essential for forming high-mannose glycans and complex N-glycans that are important for protein function.\u003cbr\u003e\nAlpha 12 Mannosidase IA has associations with congenital disorders of glycosylation (CDG) a group of diseases impacting glycoprotein synthesis and processing. Abnormal MAN1A1 activity can lead to improper glycoprotein folding causing a variety of systemic symptoms. Additionally altered MAN1A1 expression has been observed in certain types of cancer influencing tumor progression due to changes in cell surface glycosylation patterns. MAN1A1 activity closely links with other enzymes in the N-glycan maturation pathway like α-mannosidase II which further highlights its impact on glycosylation-related diseases.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46844163424425,"sku":"ab140613","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/abcam-ab140613","provider":"Iright","version":"1.0","type":"link"}